A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of HKT288, Administered Intravenously in Adult Patients With Advanced Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

Trial Profile

A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of HKT288, Administered Intravenously in Adult Patients With Advanced Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

Suspended
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs HKT 288 (Primary)
  • Indications Carcinoma; Ovarian cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 13 Sep 2017 Planned End Date changed from 30 Aug 2019 to 31 Aug 2019.
    • 29 Aug 2017 Status changed from recruiting to suspended.
    • 17 Feb 2017 According to ImmunoGen media release, Novartis dosing the first patient in a Phase 1 clinical trial in ovarian cancer and renal cell carcinoma (Dec 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top